ScreenerHero

PLRX Pliant Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · pliantrx.com
0.9900USD-3.88%Mkt Cap: 61.30M $P/E: —

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap61.30M USD
Enterprise Value-65.58M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-149.34M USD
Revenue/Share—
Last Price0.9900 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees49
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.80
PEG—
EV/EBITDA0.73
EV/Revenue—
P/S—
P/B0.43
EPS (TTM)-1.49
EPS (Forward)-1.28
52W Range
0.97002% of range1.950
52W High1.950 USD
52W Low0.9700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-82.42%
ROA-66.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.34M USD
CapEx (TTM)374.00K USD
FCF Margin—
FCF Yield-69.34%
Net Debt-129.36M USD
Net Debt/EBITDA1.44
Balance Sheet
Debt/Equity0.16
Current Ratio9.90
Quick Ratio9.64
Book Value/Sh2.37 USD
Cash/Share2.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.000 USD
Upside (mean)+102.0%
Target Range2.000 USD – 2.000 USD
# Analysts1
Ownership
Shares Out.61.92M
Float55.03M
Insiders2.23%
Institutions78.55%
Short Interest
Short Ratio8.4d
Short % Float6.10%
Short % Out.5.96%
Shares Short3.69M
Short (prev mo.)2.77M
Technical
SMA 501.101 (-10.1%)
SMA 2001.194 (-17.1%)
Beta1.28
S&P 52W Chg16.45%
Avg Vol (30d)403.45K
Avg Vol (10d)330.75K
Technical Indicators
RSI (14)31.1
MACD-0.0254
MACD Signal-0.0118
MACD Hist.-0.0135
BB Upper1.202 USD
BB Middle1.099 USD
BB Lower0.9965 USD
BB Width18.70%
ATR (14)0.0433 USD
Vol Ratio (20d)1.97x